71 related articles for article (PubMed ID: 19527683)
1. Autophagy-mediated anti-tumoral activity of imiquimod in Caco-2 cells.
Yi JY; Jung YJ; Choi SS; Hwang J; Chung E
Biochem Biophys Res Commun; 2009 Aug; 386(3):455-8. PubMed ID: 19527683
[TBL] [Abstract][Full Text] [Related]
2. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.
Wang ST; Huang SW; Kao JK; Liang SM; Chen YJ; Chen YY; Wu CY; Shieh JJ
J Dermatol Sci; 2015 May; 78(2):108-16. PubMed ID: 25766763
[TBL] [Abstract][Full Text] [Related]
4. Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line.
Huang SW; Chang SH; Mu SW; Jiang HY; Wang ST; Kao JK; Huang JL; Wu CY; Chen YJ; Shieh JJ
J Dermatol Sci; 2016 Mar; 81(3):182-91. PubMed ID: 26775629
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod induces ER stress and Ca(2+) influx independently of TLR7 and TLR8.
Nyberg WA; Espinosa A
Biochem Biophys Res Commun; 2016 May; 473(4):789-794. PubMed ID: 27003259
[TBL] [Abstract][Full Text] [Related]
6. Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
Seth A; Heo MB; Lim YT
Biomaterials; 2014 Sep; 35(27):7992-8001. PubMed ID: 24954733
[TBL] [Abstract][Full Text] [Related]
7. TLR7 and TLR8 as targets in cancer therapy.
Schön MP; Schön M
Oncogene; 2008 Jan; 27(2):190-9. PubMed ID: 18176600
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro.
Ambach A; Bonnekoh B; Nguyen M; Schön MP; Gollnick H
Mol Immunol; 2004 Apr; 40(18):1307-14. PubMed ID: 15072849
[TBL] [Abstract][Full Text] [Related]
9. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.
Stary G; Bangert C; Tauber M; Strohal R; Kopp T; Stingl G
J Exp Med; 2007 Jun; 204(6):1441-51. PubMed ID: 17535975
[TBL] [Abstract][Full Text] [Related]
10. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 7 agonists and skin.
Novak N; Yu CF; Bieber T; Allam JP
Drug News Perspect; 2008 Apr; 21(3):158-65. PubMed ID: 18560614
[TBL] [Abstract][Full Text] [Related]
12. TLR7 Stimulation With Imiquimod Induces Selective Autophagy and Controls
Lee HJ; Kang SJ; Woo Y; Hahn TW; Ko HJ; Jung YJ
Front Microbiol; 2020; 11():1684. PubMed ID: 32765474
[TBL] [Abstract][Full Text] [Related]
13. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
Schön MP; Wienrich BG; Drewniok C; Bong AB; Eberle J; Geilen CC; Gollnick H; Schön M
J Invest Dermatol; 2004 May; 122(5):1266-76. PubMed ID: 15140231
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells.
Shojaei H; Oberg HH; Juricke M; Marischen L; Kunz M; Mundhenke C; Gieseler F; Kabelitz D; Wesch D
Cancer Res; 2009 Nov; 69(22):8710-7. PubMed ID: 19887600
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
16. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
[TBL] [Abstract][Full Text] [Related]
18. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
19. The antitumoral mode of action of imiquimod and other imidazoquinolines.
Schön M; Schön MP
Curr Med Chem; 2007; 14(6):681-7. PubMed ID: 17346155
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
Huang SW; Wang ST; Chang SH; Chuang KC; Wang HY; Kao JK; Liang SM; Wu CY; Kao SH; Chen YJ; Shieh JJ
J Invest Dermatol; 2020 Sep; 140(9):1771-1783.e6. PubMed ID: 32035924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
